{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T08:35:09Z","timestamp":1793781309298,"version":"4.6.1"},"reference-count":48,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007659","name":"Bayer HealthCare Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.clgc.2025.102386","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T20:08:34Z","timestamp":1750277314000},"page":"102386","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Real-World Treatment Patterns and Survival in People With Metastatic Castration-Resistant Prostate Cancer Following Metastatic Hormone-Sensitive Disease Between 2020 and 2023 in the United States"],"prefix":"10.1016","volume":"23","author":[{"given":"Amit D.","family":"Raval","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9658-8854","authenticated-orcid":false,"given":"Guifang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Korn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Bernthaler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niculae","family":"Constantinovici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8104-6419","authenticated-orcid":false,"given":"Stephen J.","family":"Freedland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2025.102386_bib0001","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clgc.2025.102386_bib0002","unstructured":"Eastham JA, Auffenberg GB, Barocas DA, et al. Clinically localized Prostate cancer: AUA\/ASTRO guideline 2022. Available at https:\/\/www.auanet.org\/guidelines-and-quality\/guidelines\/oncology-guidelines\/prostate-cancer (Accessed 22 Jan 2025)."},{"key":"10.1016\/j.clgc.2025.102386_bib0003","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1097\/JU.0000000000003452","article-title":"Updates to advanced prostate cancer: AUA\/SUO guideline (2023)","volume":"209","author":"Lowrance","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2025.102386_bib0004","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s11523-022-00899-6","article-title":"Pattern of clinical progression until metastatic castration-resistant Prostate Cancer: an epidemiological study from the European Prostate Cancer Registry","volume":"17","author":"Verry","year":"2022","journal-title":"Target Oncol"},{"key":"10.1016\/j.clgc.2025.102386_bib0005","unstructured":"Docetaxel EU summary of product characteristics. Available at https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/docetaxel-accord-epar-product-information_en.pdf (Accessed 23 Oct 2024)."},{"key":"10.1016\/j.clgc.2025.102386_bib0006","unstructured":"Docetaxel US prescribing information. Available at https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/022234s022lbl.pdf (Accessed 23 Oct 2024)."},{"key":"10.1016\/j.clgc.2025.102386_bib0007","unstructured":"Cabazitaxel EU summary of product characteristics. Available at https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/jevtana-epar-product-information_en.pdf (Accessed 23 Oct 2024)."},{"key":"10.1016\/j.clgc.2025.102386_bib0008","unstructured":"Cabazitaxel US prescribing information. Available at https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/201023s026lbl.pdf (Accessed 23 Oct 2024)."},{"key":"10.1016\/j.clgc.2025.102386_bib0009","unstructured":"Abiraterone acetate US prescribing information. Available at https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/202379s035lbl.pdf (Accessed 23 Oct 2024)."},{"key":"10.1016\/j.clgc.2025.102386_bib0010","unstructured":"Abiraterone acetate EU summary of product characteristics. Available at https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zytiga-epar-product-information_en.pdf (Accessed 23 Oct 2024)."},{"key":"10.1016\/j.clgc.2025.102386_bib0011","unstructured":"Enzalutamide US prescribing information. Available at https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/213674s010,203415s022lbl.pdf (accessed 23 Oct 2024)."},{"key":"10.1016\/j.clgc.2025.102386_bib0012","unstructured":"Enzalutamide EU summary of product charcteristics. Available at https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xtandi-epar-product-information_en.pdf (accessed 23 Oct 2024)."},{"key":"10.1016\/j.clgc.2025.102386_bib0013","unstructured":"Olaparib US prescribing information. Available at https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/208558s028lbl.pdf (Accessed 23 Oct 2024)."},{"key":"10.1016\/j.clgc.2025.102386_bib0014","unstructured":"Olaparib EU summary of product characteristcs. Available at https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lynparza-epar-product-information_en.pdf (Accessed 23 Oct 2024)."},{"key":"10.1016\/j.clgc.2025.102386_bib0015","unstructured":"Rucaparib US prescribing information. Available at https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/209115s013lbl.pdf (Accessed 23 Oct 2024)."},{"key":"10.1016\/j.clgc.2025.102386_bib0016","unstructured":"Talazoparib US prescribing information. Available at https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/211651s012lbl.pdf (Accessed 23 Oct 2024)."},{"key":"10.1016\/j.clgc.2025.102386_bib0017","unstructured":"Talazoparib EU summary of product characteristics. Available at https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/talzenna-epar-product-information_en.pdf (Accessed 23 Oct 2024)."},{"key":"10.1016\/j.clgc.2025.102386_bib0018","unstructured":"Niraparib\/abiraterone acetate fixed-dose tablets US prescribing information. Available at https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/216793s000lbl.pdf (Accessed 23 Oct 2024)."},{"key":"10.1016\/j.clgc.2025.102386_bib0019","unstructured":"Niraparib\/abiraterone acetate fixed-dose tablets EU summary of product characteristics. Available at https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/akeega-epar-product-information_en.pdf (Accessed 23 Oct 2024)."},{"key":"10.1016\/j.clgc.2025.102386_bib0020","unstructured":"Radium-223 dichloride US prescribing information. Available at https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/203971s016lbl.pdf (Accessed 23 Oct 2024)."},{"key":"10.1016\/j.clgc.2025.102386_bib0021","unstructured":"Radium-223 dichloride EU summary of product characteristics. Available at https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xofigo-epar-product-information_en.pdf (Accessed 23 Oct 2024)."},{"key":"10.1016\/j.clgc.2025.102386_bib0022","unstructured":"Lutetium-177 vipivotide tetraxetan US prescribing information. Available at https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/215833s000lbl.pdf (Accessed 23 Oct 2024)."},{"key":"10.1016\/j.clgc.2025.102386_bib0023","unstructured":"Lutetium-177 vipivotide tetraxetan EU summary of product characteristics. Available at https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/pluvicto-epar-product-information_en.pdf (Accessed 23 Oct 2024)."},{"key":"10.1016\/j.clgc.2025.102386_bib0024","unstructured":"Sipuleucel-T US prescribing informaiton. Available at https:\/\/www.fda.gov\/media\/78511\/download (Accessed 23 Oct 2024)."},{"key":"10.1016\/j.clgc.2025.102386_bib0025","unstructured":"Pembrolizumab US prescribing information. Available at https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/125514s161lbl.pdf (Accessed 23 Oct 2024)."},{"key":"10.1016\/j.clgc.2025.102386_bib0026","unstructured":"Darolutamide EU summary of product characteristics. Available at https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/nubeqa-epar-product-information_en.pdf (Accessed 23 Oct 2024)."},{"key":"10.1016\/j.clgc.2025.102386_bib0027","unstructured":"Darolutamide US prescribing information. Available at https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/212099s004lbl.pdf (Accessed 23 Oct 2024)."},{"key":"10.1016\/j.clgc.2025.102386_bib0028","unstructured":"Apalutamide US prescribing information. Available at https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/210951s016lbl.pdf (Accessed 23 Oct 2024)."},{"key":"10.1016\/j.clgc.2025.102386_bib0029","unstructured":"Apalutamide EU summary of product characteristics. Available at https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/erleada-epar-product-information_en.pdf (Accessed 23 Oct 2024)."},{"key":"10.1016\/j.clgc.2025.102386_bib0030","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2025.102386_bib0031","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2025.102386_bib0032","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2025.102386_bib0033","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1200\/JCO.22.00193","article-title":"Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer","volume":"40","author":"Armstrong","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2025.102386_bib0034","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1007\/s12325-022-02073-w","article-title":"Real-world treatment patterns in metastatic castration-resistant prostate cancer across Europe (France, Germany, Italy, Spain, and the United Kingdom) and Japan","volume":"39","author":"Leith","year":"2022","journal-title":"Adv Ther."},{"key":"10.1016\/j.clgc.2025.102386_bib0035","doi-asserted-by":"crossref","first-page":"e737","DOI":"10.1093\/oncolo\/oyad046","article-title":"Real-world treatment patterns among patients with metastatic castration-resistant prostate cancer: results from an international study","volume":"28","author":"Barata","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.clgc.2025.102386_bib0036","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1080\/03007995.2021.1879753","article-title":"Identification of patients with metastatic castration-sensitive or metastatic castration-resistant prostate cancer using administrative health claims and laboratory data","volume":"37","author":"Freedland","year":"2021","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clgc.2025.102386_bib0037","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1053\/j.seminoncol.2023.03.001","article-title":"Tumor testing and treatment patterns in veterans with metastatic castration-resistant prostate cancer","volume":"50","author":"Hung","year":"2023","journal-title":"Semin Oncol"},{"key":"10.1016\/j.clgc.2025.102386_bib0038","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.clgc.2019.12.019","article-title":"Treatment patterns and outcomes in patients with metastatic castration-resistant prostate cancer in a real-world clinical practice setting in the United States","volume":"18","author":"George","year":"2020","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2025.102386_bib0039","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41391-023-00725-8","article-title":"Real-world treatment patterns and overall survival among men with metastatic castration-resistant prostate cancer (mCRPC) in the US Medicare population","volume":"27","author":"Freedland","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.clgc.2025.102386_bib0040","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1007\/s12325-021-01823-6","article-title":"Real-world treatment patterns and overall survival of patients with metastatic castration-resistant prostate cancer in the US prior to PARP inhibitors","volume":"38","author":"Shore","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.clgc.2025.102386_bib0041","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ejca.2023.02.018","article-title":"Management of patients with advanced prostate cancer-metastatic and\/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022","volume":"185","author":"Gillessen","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2025.102386_bib0042","doi-asserted-by":"crossref","first-page":"1 e1-1 e10","DOI":"10.1016\/j.urolonc.2019.09.027","article-title":"Real-world practice patterns in veterans with metastatic castration-resistant prostate cancer","volume":"38","author":"Halwani","year":"2020","journal-title":"Urol Oncol"},{"issue":"6","key":"10.1016\/j.clgc.2025.102386_bib0043","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1200\/JCO.2023.41.6_suppl.64","article-title":"Real-world treatment patterns and progression-free survival among patients with metastatic castration-resistant prostate cancer: examining the benefits of sequential androgen receptor pathway inhibitor use [Abtsract no. 64]","volume":"41","author":"Patel","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2025.102386_bib0044","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41391-020-0222-6","article-title":"Sequential therapy of abiraterone and enzalutamide in castration-resistant prostate cancer: a systematic review and meta-analysis","volume":"23","author":"Mori","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.clgc.2025.102386_bib0045","series-title":"Presented at the European Medical Society for Oncology Congress","article-title":"A randomized multicenter open-label phase III trial comparing enzalutamide vs a combination of radium-223 and enzalutamide in asymptomatic or mildly symptomatic patients with bone metastatic mCRPC [oral presentation]","author":"Gillessen","year":"2024"},{"issue":"5","key":"10.1016\/j.clgc.2025.102386_bib0046","article-title":"Overall survival and quality of life with [177Lu] Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in poor-risk, metastatic, castration-resistant prostate cancer in ENZA-p (ANZUP 1901) [abtsract no. 17]","volume":"43","author":"Emmett","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2025.102386_bib0047","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1200\/JCO.20.03488","article-title":"Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study","volume":"39","author":"Chi","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2025.102386_bib0048","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1177\/10781552211015767","article-title":"Global changes to the chemotherapy service during the covid-19 pandemic","volume":"27","author":"Chow","year":"2021","journal-title":"J Oncol Pharm Pract"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325000862?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325000862?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T15:26:30Z","timestamp":1757517990000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767325000862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1558767325000862"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102386","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Treatment Patterns and Survival in People With Metastatic Castration-Resistant Prostate Cancer Following Metastatic Hormone-Sensitive Disease Between 2020 and 2023 in the United States","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102386","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102386"}}